Lnc2Cancer

Experimentally Supported Human LncRNA and Cancer Associations Database

LncRNA centric

Cancer centric

Advanced search

Drug resistant

Circulating

Prognosis

Detail


   LncRNA Name ANRIL
   Synonyms CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS
   Region GRCh38_9:21994778-22121097    Sequence
   Ensembl ENSG00000240498
   RefSeq NR_003529
   Circulating
   Drug-resisitant
   Prognostic
   MiRNA
   Variant
   TF
   Methylation
   Cancer Name nasopharyngeal cancer
   ICD-0-3 C11  
   Methods qPCR, RNAi, Luciferase reporter assay, MTT assay etc.
   Sample NPC tissues, cell lines (CNE1, CNE2, S18, HONE1, and 5-8F)
   Expression Pattern up-regulated
   Function Description

ANRIL was highly expressed and let-7a was downregulated in NPC tissues and cells. Luciferase assay revealed that ANRIL could negatively regulate miR-let-7a expression. ANRIL knockdown inhibited NPC cell proliferation and induced apoptosis, while anti-let-7a reversed these effects. Combination treatment of si-ANRIL and DDP led to a lower viability, a more DNA strand breaks damage and a higher comet tail length compared with any single treatment, whereas let-7a inhibitor abolished these effects. Furthermore, depletion of ANRIL exacerbated DDP-induced cytotoxicity in NPC cells in vivo.

   Pubmed ID 28117929
   Year 2017
   Title Downregulation of lncRNA ANRIL represses tumorigenicity and enhances cisplatin-induced cytotoxicity via regulating microRNA let-7a in nasopharyngeal carcinoma.
   External Links
   Links for  ANRIL GenBank       HGNC       lncrnadb       Noncode
   Links for  nasopharyngeal cancer Omim       Cosmic

CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.